Sexually Transmitted Diseases

How 1 provider is training medical peers to offer PrEP education and prescribe it.

Bias against injection drug users can inhibit them from receiving potentially lifesaving care, such as HIV pre-exposure prophylaxis (PrEP). Community-based responses like syringe service programs help combat this stigma.

Fenway Health’s Pride in Our Health podcast is an example of new voices being heard, and an alternative means of getting health information to the general public.

Adding genotypic resistance testing (GRT) to routine care did not improve HIV virologic outcomes for patients for whom first-line ART failed, the study authors wrote.

Long-acting cabotegravir plus rilpivirine worked with or without a lead-in for ART-naïve HIV patients.

A new study looks at this population and what factors affect outcomes, including diagnosis. This is significant not only for pandemic response, but also preparedness for vulnerable patient populations.

People who inject drugs (PWID) remain at risk of HIV infection, according to a recent report by the CDC, which found HIV infection and HIV-associated behaviors remained steady between 2015 and 2018.

29% of cisgender men who have sex with men acquired HIV despite being designated as “low risk.”

In Gilead’s BICSTaR trial of their full HIV treatment regimen Biktarvy, 97% of treatment-naïve adults and 96% of treatment-experienced adults achieved virological suppression after 1 year.

The increasing presence of multiple non-AIDS comorbidities in women and others living with HIV challenges clinicians to steer away from the approach of optimizing individual chronic conditions but to think more holistically.

Merck recently announced results looking at their islatravir implant studied for HIV prevention for 3 months. The long-term goal is to have the implant last 12 months following administration.

Children living with HIV have a new once-daily treatment option to maintain virologic suppression.

Comparing 2020 to 2019, investigators saw a reduction in the number of HIV tests, the number of in-person consultations, and new enrollments in care, due to the disruption in HIV care throughout the COVID-19 pandemic.

There are MSM who are indicated for PrEP use that don’t use it, and vice versa, the study authors found.

This promising class of therapy is an expanding treatment option for people who are looking for HIV prevention offerings.

The TakeMeHome program, a public-private partnership to distribute HIV self-test home kits to at-risk populations, is reaching at-risk individuals who weren’t otherwise accessing testing.

The HIV In-hospital Mortality Prediction (HIV-IMP) risk score showed good discrimination and calibration and may be useful in guiding clinical decision-making.

A recent study measured premature deaths among people with HIV by sex, race, and HIV risk factor.

Pregnant women infected with certain strains of human papillomavirus during pregnancy had a nearly fourfold greater risk of preterm labor.

People who inject drugs are at high-risk for HIV infection, but very few are interested in PrEP prescriptions.

Mortality rates of children with HIV may be underreported due to lack of patient follow-up and the usage of routine program data.

Cabotegravir has a target date of January 24, 2022 and would become the first long-acting HIV PrEP therapy approved.

England has been meeting and exceeding its HIV diagnosis and treatment goals set by UNAIDS.

Parentless youth living on the streets had the highest rates of HIV and death, but extended-family living situations were not necessarily better than institutional care.

The therapy, known as EBT-101, works by eliminating HIV-infected DNA from the genome.

To address PrEP implementation in Kenya, a team of researchers evaluated practices and contextual modifications across public HIV clinics.

Antiretroviral therapy for HIV offers a protective outcome against preterm birth for pregnant women with HIV.

The University of Miami (UM) has a community-based mobile clinic that offers PrEP counseling along with other medical services to those who might not otherwise have access to or seek clinical care.

Higher HIV viral loads and additional heart disease factors increase the risk as well.